Advanced CRC in combination w/ 5-fluorouracil (5-FU) & folinic acid in patients w/o prior chemotherapy for advanced disease. Monotherapy in patients who have failed an established 5-FU-containing treatment regimen.
Monotherapy 125 mg/m2 IV infusion over 30-90 min every wk or 250 mg/m2 IV infusion over 30-90 min every 2 wk, or 350 mg/m2 IV infusion over 30-90 min every 3 wk. Combination w/ 5-FU & leucovorin Irinotecan 125 mg/m2, bolus 5-FU 500 mg/m2 & bolus leucovorin 20 mg/m2 for 6-wk cycle or irinotecan 180 mg/m2, bolus 5-FU 400 mg/m2, 5-FU infusion 600 mg/m2 & leucovorin 200 mg/m2 for 6-wk cycle.
Hypersensitivity reactions. Discontinue if neutropenic fever occur or ANC <1,000/mm3. Not to be used in patients w/ severe bone marrow failure. Cholinergic symptoms; previous pelvic/abdominal irradiation; early & late diarrhoea, colitis/ileus; chronic inflammatory bowel disease &/or bowel obstruction; nausea, vomiting; dizziness; preexisting lung disease; gastric cancer. Patients w/ poor performance status, reduced UGT1A1 activity. Avoid extravasation & monitor infusion site for signs of inflammation. Monitor hepatic function prior to therapy. Avoid use w/ live or live attenuated vaccine. Concomitant use w/ pneumotoxic drugs, radiation therapy & colony stimulating factors. Unsuitable in hereditary fructose intolerance. May affect ability to drive & use machines. Not recommended on dialysis patients. Renal & hepatic impairment. Women of childbearing potential should use effective contraception during & for 6 mth after last dose. Male patients should use effective contraception during & for 3 mth after last dose. Avoid use during pregnancy. Not recommended during lactation. Childn. Elderly >65 yr.
Sign Out
